Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.

Pathmanathan AU, McNair HA, Schmidt MA, Brand DH, Delacroix L, Eccles CL, Gordon A, Herbert T, van As NJ, Huddart RA, Tree AC.

Br J Radiol. 2019 Mar;92(1095):20180948. doi: 10.1259/bjr.20180948. Epub 2019 Jan 24.

PMID:
30676772
2.

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.

Tan MP, Attard G, Huddart RA.

Int J Mol Sci. 2018 Aug 29;19(9). pii: E2568. doi: 10.3390/ijms19092568. Review.

3.

Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, Lievens Y, Sebag-Montefiore D, Coles CE.

Br J Cancer. 2018 Aug;119(4):389-407. doi: 10.1038/s41416-018-0201-z. Epub 2018 Jul 31. Review.

4.

Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology.

Loveday C, Law P, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration, The PRACTICAL Consortium, Reid A, Huddart RA, Houlston RS, Turnbull C.

Eur Urol. 2018 Sep;74(3):248-252. doi: 10.1016/j.eururo.2018.05.036. Epub 2018 Jun 21.

5.

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

Huddart RA, Reid AM.

Adv Urol. 2018 Apr 2;2018:8781698. doi: 10.1155/2018/8781698. eCollection 2018. Review.

6.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

7.

Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer.

Loveday C, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N, Reid A, Huddart RA, Houlston RS, Turnbull C.

Oncotarget. 2017 Dec 7;9(16):12630-12638. doi: 10.18632/oncotarget.23117. eCollection 2018 Feb 27.

8.

IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.

Selfe J, Goddard NC, McIntyre A, Taylor KR, Renshaw J, Popov SD, Thway K, Summersgill B, Huddart RA, Gilbert DC, Shipley JM.

J Pathol. 2018 Feb;244(2):242-253. doi: 10.1002/path.5008. Epub 2018 Jan 10.

9.

Positron Emission Tomography Scanning for Recurrent Bladder Cancer.

Wilson JM, Huddart RA.

Eur Urol Focus. 2016 Jun;2(2):219-220. doi: 10.1016/j.euf.2016.02.002. Epub 2016 Mar 19.

PMID:
28723538
10.

Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.

Litchfield K, Levy M, Orlando G, Loveday C, Law PJ, Migliorini G, Holroyd A, Broderick P, Karlsson R, Haugen TB, Kristiansen W, Nsengimana J, Fenwick K, Assiotis I, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration; PRACTICAL Consortium, Bishop DT, Reid A, Huddart RA, Shipley J, Grotmol T, Wiklund F, Houlston RS, Turnbull C.

Nat Genet. 2017 Jul;49(7):1133-1140. doi: 10.1038/ng.3896. Epub 2017 Jun 12.

11.

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.

Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren DB, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E.

BJU Int. 2017 Nov;120(5):639-650. doi: 10.1111/bju.13900. Epub 2017 May 29.

12.

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T.

J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828. Epub 2017 Apr 12.

PMID:
28402747
13.

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S.

J Clin Oncol. 2017 Jan;35(1):48-55. Epub 2016 Oct 28.

PMID:
28034079
14.

The present and future of serum diagnostic tests for testicular germ cell tumours.

Murray MJ, Huddart RA, Coleman N.

Nat Rev Urol. 2016 Dec;13(12):715-725. doi: 10.1038/nrurol.2016.170. Epub 2016 Oct 18. Review.

PMID:
27754472
15.

The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.

Pathmanathan AU, Alexander EJ, Huddart RA, Tree AC.

Future Oncol. 2016 Nov;12(21):2495-2511. Epub 2016 Jun 20. Review.

PMID:
27322113
16.

The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.

Litchfield K, Levy M, Huddart RA, Shipley J, Turnbull C.

Nat Rev Urol. 2016 Jul;13(7):409-19. doi: 10.1038/nrurol.2016.107. Epub 2016 Jun 14. Review.

PMID:
27296647
17.

Identification of four new susceptibility loci for testicular germ cell tumour.

Litchfield K, Holroyd A, Lloyd A, Broderick P, Nsengimana J, Eeles R, Easton DF, Dudakia D, Bishop DT, Reid A, Huddart RA, Grotmol T, Wiklund F, Shipley J, Houlston RS, Turnbull C.

Nat Commun. 2015 Oct 27;6:8690. doi: 10.1038/ncomms9690.

18.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T.

J Clin Oncol. 2016 Feb 1;34(4):345-51. doi: 10.1200/JCO.2015.62.7000. Epub 2015 Oct 12.

19.

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, Stoneham SJ, Pashankar F, Stark D, Shaikh F, Gershenson DM, Covens A, Hurteau J, Stenning SP, Feldman DR, Grimison PS, Huddart RA, Sweeney C, Powles T, Lopes LF, dos Santos Agular S, Chinnaswamy G, Khaleel S, Abouelnaga S, Hale JP, Frazier AL.

J Clin Oncol. 2015 Sep 20;33(27):3018-28. doi: 10.1200/JCO.2014.60.5337. Epub 2015 Aug 24. Review. Erratum in: J Clin Oncol. 2015 Nov 20;33(33):3981.

20.

The role of 18F-FDG PET/CT in the management of testicular cancers.

Cook GJ, Sohaib A, Huddart RA, Dearnaley DP, Horwich A, Chua S.

Nucl Med Commun. 2015 Jul;36(7):702-8. doi: 10.1097/MNM.0000000000000303.

PMID:
25757201

Supplemental Content

Loading ...
Support Center